ArticleOncotarget2017
Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients.Cancer medicine · 2023Article
- Influence of Long Non-Coding RNA in the Regulation of Cancer Stem Cell Signaling Pathways.Cells · 2022Review
- Mechanisms of Long Non-Coding RNAs in Biological Characteristics and Aerobic Glycolysis of Glioma.International journal of molecular sciences · 2021Review
- LncRNAs associated with glioblastoma: From transcriptional noise to novel regulators with a promising role in therapeutics.Molecular therapy. Nucleic acids · 2021Review
- Potential of long non-coding RNAs as a therapeutic target and molecular markers in glioblastoma pathogenesis.Heliyon · 2021Review
- LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway.Cellular and molecular neurobiology · 2021Article
- Prognostic and Predictive Value of m6A "Eraser" Related Gene Signature in Gastric Cancer.Frontiers in oncology · 2021Article
- Promoting Prognostic Model Application: A Review Based on Gliomas.Journal of oncology · 2021Review
- Circulating biomarkers in patients with glioblastoma.British journal of cancer · 2020Review
- Prognostic and Predictive Value of a Long Non-coding RNA Signature in Glioma: A lncRNA Expression Analysis.Frontiers in oncology · 2020Article
- Blocking lncRNA MALAT1/miR-199a/ZHX1 Axis Inhibits Glioblastoma Proliferation and Progression.Molecular therapy. Nucleic acids · 2019Article
- A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs.Molecular neurobiology · 2019Article
- Linc00423 as a tumor suppressor in retroperitoneal liposarcoma via activing MAPK signaling pathway through destabilizing of NFATC3.Cell death & disease · 2019Article
- A prognostic signature based on three non-coding RNAs for prediction of the overall survival of glioma patients.FEBS open bio · 2019Article
- Characterization of Transcriptome Transition Associates Long Noncoding RNAs with Glioma Progression.Molecular therapy. Nucleic acids · 2018Article
- Long non-coding RNAs in brain tumours: Focus on recent epigenetic findings in glioma.Journal of cellular and molecular medicine · 2018Review
- The long non-coding RNA uc.4 influences cell differentiation through the TGF-beta signaling pathway.Experimental & molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs have been shown to be associated with cancer development and progression, demonstrating potential applications as novel diagnostic or prognostic molecular markers in clinical management and treatment. However, the functional significance of lncRNAs in the development and malignant progression of gliomas is still unclear and needed to be further explored. we first obtained genome-wide lncRNA expression profiles in a large cohort of patients with gliomas from the Gene Expression Omnibus database using microarray probes repurposing method and investigated the lncRNA expression patterns during the tumorigenesis and malignant progression of gliomas. By using differential expression analysis, we identified a large number of lncRNAs that were associated with the tumorigenesis and malignant progression of gliomas in the training dataset and showed their robustness in the testing dataset. Subsequently, we identified a novel four-lncRNA signature which was closely related to the prognosis of patients with GBM. The prognostic value of this signature was verified in the test set of 80 patients. Functional analysis suggested that the four lncRNAs associated with survival of patients with GBM may be involved in cancer-related biological processes and pathways and their deregulation may lead to GBM tumorigenesis and progression. These novel lncRNA biomarkers will improve our understanding of the molecular mechanisms during the development and progression of glioma and provide novel diagnostic or prognostic markers and therapeutic targets for gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.